1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Autoimmune Disorders – Pipeline Review, H1 2013

Autoimmune Disorders – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 336 pages

Autoimmune Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Autoimmune Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Autoimmune Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autoimmune Disorders. Autoimmune Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Autoimmune Disorders.
- A review of the Autoimmune Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Autoimmune Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Autoimmune Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Autoimmune Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Autoimmune Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 13
Introduction 14
Global Markets Direct Report Coverage 14
Autoimmune Disorders Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Autoimmune Disorders 16
Autoimmune Disorders Therapeutics under Development by Companies 18
Autoimmune Disorders Therapeutics under Investigation by Universities/Institutes 33
Late Stage Products 36
Comparative Analysis 36
Mid Clinical Stage Products 37
Comparative Analysis 37
Early Clinical Stage Products 38
Comparative Analysis 38
Discovery and Pre-Clinical Stage Products 39
Comparative Analysis 39
Autoimmune Disorders Therapeutics - Products under Development by Companies 40
Autoimmune Disorders Therapeutics - Products under Investigation by Universities/Institutes 61
Companies Involved in Autoimmune Disorders Therapeutics Development 63
Alcon, Inc. 63
Johnson and Johnson 64
Boehringer Ingelheim GmbH 65
F. Hoffmann-La Roche Ltd. 66
Kyowa Hakko Kirin Co., Ltd. 67
Amgen Inc. 68
Antares Pharma, Inc. 69
Sanofi-Aventis 70
Eli Lilly and Company 71
GlaxoSmithKline plc 72
Genentech, Inc. 73
MedImmune LLC 74
Biotest AG 75
Merck and Co., Inc. 76
Ablynx 77
AbGenomics International, Inc. 78
Emergent BioSolutions Inc. 79
Novo Nordisk A/S 80
BioLineRx, Ltd. 81
MediGene AG 82
Nycomed International Management GmbH 83
TiGenix NV 84
Actelion Ltd 85
Astellas Pharma Inc. 86
Biocon Limited 87
Eisai Co., Ltd. 88
Elan Corporation, plc 89
Glenmark Pharmaceuticals Ltd. 90
GTC Biotherapeutics, Inc. 91
Japan Tobacco Inc. 92
Kissei Pharmaceutical Co., Ltd. 93
LEO Pharma A/S 94
Pfizer Inc. 95
Rigel Pharmaceuticals, Inc. 96
Santarus, Inc. 97
Teva Pharmaceutical Industries Limited 98
UCB Group 99
Genmab A/S 100
Hadasit Medical Research Services and Development Ltd 101
Exelixis, Inc. 102
Celgene Corporation 103
Onyx Pharmaceuticals, Inc. 104
Incyte Corporation 105
Merck KGaA 106
4SC AG 107
Evotec Aktiengesellschaft 108
Genesis Research and Development Corporation Ltd. 109
Hollis-Eden Pharmaceuticals, Inc. 110
Celldex Therapeutics, Inc. 111
Momenta Pharmaceuticals, Inc. 112
Active Biotech AB 113
IMMUNOMEDICS, INC 114
Idera Pharmaceuticals, Inc. 115
Karo Bio 116
Almirall, S.A. 117
NexMed, Inc. 118
Cleveland BioLabs, Inc. 119
Compugen Ltd. 120
Ore Pharmaceuticals Inc 121
Pharmos Corporation 122
Accentia Biopharmaceuticals, Inc. 123
Arena Pharmaceuticals, Inc. 124
Portola Pharmaceuticals, Inc. 125
Chelsea Therapeutics, Inc. 126
KOLON LIFE SCIENCE INC. 127
NeoStem, Inc. 128
Pharmacyclics, Inc. 129
Protalix BioTherapeutics, Inc. 130
Dynavax Technologies Corporation 131
Tolerx, Inc. 132
ProMetic Life Sciences Inc. 133
XOMA Ltd. 134
Antisoma plc 135
Transgene SA 136
Hanall Pharmaceutical Co., Ltd. 137
Panacea Biotec Limited 138
Catalyst Biosciences, Inc. 139
Innate Pharma SA 140
DiaMedica Inc. 141
Hansa Medical AB 142
R-Tech Ueno, Ltd. 143
Cellerant Therapeutics, Inc. 144
University of Erlangen-Nurnberg 145
Morphotek, Inc. 146
Affitech A/S 147
Debiopharm Group 148
Advinus Therapeutics Pvt. Ltd. 149
Axxam SpA 150
Alba Therapeutics Corporation 151
Ambit Biosciences Corporation 152
Viron Therapeutics, Inc. 153
Deltanoid Pharmaceuticals Inc. 154
Immupharma Plc 155
Palau Pharma S.A 156
Memgen, LLC. 157
Molecular Partners AG 158
Pieris AG 159
Phenex Pharmaceuticals AG 160
conoGenetix biosciences GmbH 161
Hutchison MediPharma Limited 162
CREABILIS Therapeutics S.r.l. 163
ERYtech Pharma 164
Affibody AB 165
Argos Therapeutics, Inc. 166
Aegera Therapeutics Inc. 167
Alligator Bioscience AB 168
Altor BioScience Corporation 169
Anacor Pharmaceuticals, Inc. 170
AnaptysBio, Inc. 171
Telormedix SA 172
Therapeutics Incorporated 173
Allozyne, Inc. 174
ZaBeCor Pharmaceuticals 175
Chiome Bioscience, Inc. 176
MacroGenics, Inc. 177
Recoly N.V. 178
Astion Pharma A/S 179
Five Prime Therapeutics, Inc. 180
Vaccinex, Inc. 181
Pantarhei Bioscience BV 182
Kineta, Inc. 183
Deciphera Pharmaceuticals, LLC 184
MSM Protein Technologies, Inc. 185
Reata Pharmaceuticals, Inc. 186
Vascular Biogenics Ltd. 187
Xention Limited 188
TcL Pharma SAS 189
Biotica Technology Ltd 190
VLST Corporation, Inc. 191
Virobay Inc. 192
NKT Therapeutics, Inc. 193
Omeros Corporation 194
The Scripps Research Institute 195
Xencor, Inc. 196
Cornerstone Therapeutics Inc. 197
SBI Biotech Co., Ltd. 198
iBio, Inc. 199
ChemoCentryx, Inc. 200
4-Antibody AG 201
CBio Limited 202
VentiRx Pharmaceuticals, Inc. 203
Anthera Pharmaceuticals‚ Inc. 204
Biokine Therapeutics Ltd. 205
KYORIN Pharmaceutical Co., Ltd. 206
Avesthagen Limited 207
Maruho Co.,Ltd. 208
KAHR medical Ltd. 209
SuppreMol GmbH 210
NasVax Ltd. 211
Centocor Ortho Biotech, Inc. 212
AIMM Therapeutics B.V. 213
Zymeworks Inc. 214
Anaphore, Inc. 215
Dynamix Pharmaceuticals Ltd. 216
Amplimmune, Inc. 217
Lycera Corp. 218
Perseid Therapeutics LLC 219
LFB Biotechnologies, S.A.S.U. 220
Interprotein Corporation 221
CalciMedica, Inc. 222
Zyngenia, Inc. 223
MicroDose Therapeutx, Inc. 224
Bio Sidus S.A. 225
Gliknik, Inc. 226
XBiotech USA, Inc. 227
RaQualia Pharma Inc. 228
Advancell 229
Autoimmune Disorders - Therapeutics Assessment 230
Assessment by Monotherapy Products 230
Assessment by Combination Products 231
Assessment by Route of Administration 232
Assessment by Molecule Type 235
Drug Profiles 238
forigerimod - Drug Profile 238
brodalumab - Drug Profile 240
ixekizumab - Drug Profile 242
tabalumab - Drug Profile 244
tofacitinib - Drug Profile 246
belimumab - Drug Profile 250
apremilast - Drug Profile 253
secukinumab - Drug Profile 255
tocilizumab - Drug Profile 258
certolizumab pegol - Drug Profile 261
blisibimod - Drug Profile 267
ustekinumab - Drug Profile 269
epratuzumab - Drug Profile 271
methotrexate - Drug Profile 275
tildrakizumab - Drug Profile 277
immune globulin intravenous (human) - Drug Profile 278
LAS-41008 - Drug Profile 279
Autoimmune Disorders Therapeutics - Drug Profile Updates 280
Autoimmune Disorders Therapeutics - Discontinued Products 312
Autoimmune Disorders Therapeutics - Dormant Products 314
Autoimmune Disorders - Product Development Milestones 326
Featured News and Press Releases 326
Appendix 334
Methodology 334
Coverage 334
Secondary Research 334
Primary Research 334
Expert Panel Validation 334
Contact Us 335
Disclaimer 335



List of Tables

Number of Products Under Development for Autoimmune Disorders, H1 2013 17
Products under Development for Autoimmune Disorders - Comparative Analysis, H1 2013 18
Number of Products under Development by Companies, H1 2013 20
Number of Products under Development by Companies, H1 2013 (Contd..1) 21
Number of Products under Development by Companies, H1 2013 (Contd..2) 22
Number of Products under Development by Companies, H1 2013 (Contd..3) 23
Number of Products under Development by Companies, H1 2013 (Contd..4) 24
Number of Products under Development by Companies, H1 2013 (Contd..5) 25
Number of Products under Development by Companies, H1 2013 (Contd..6) 26
Number of Products under Development by Companies, H1 2013 (Contd..7) 27
Number of Products under Development by Companies, H1 2013 (Contd..8) 28
Number of Products under Development by Companies, H1 2013 (Contd..9) 29
Number of Products under Development by Companies, H1 2013 (Contd..10) 30
Number of Products under Development by Companies, H1 2013 (Contd..11) 31
Number of Products under Development by Companies, H1 2013 (Contd..12) 32
Number of Products under Development by Companies, H1 2013 (Contd..13) 33
Number of Products under Investigation by Universities/Institutes, H1 2013 35
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 36
Comparative Analysis by Late Stage Development, H1 2013 37
Comparative Analysis by Mid Clinical Stage Development, H1 2013 38
Comparative Analysis by Early Clinical Stage Development, H1 2013 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 40
Products under Development by Companies, H1 2013 41
Products under Development by Companies, H1 2013 (Contd..1) 42
Products under Development by Companies, H1 2013 (Contd..2) 43
Products under Development by Companies, H1 2013 (Contd..3) 44
Products under Development by Companies, H1 2013 (Contd..4) 45
Products under Development by Companies, H1 2013 (Contd..5) 46
Products under Development by Companies, H1 2013 (Contd..6) 47
Products under Development by Companies, H1 2013 (Contd..7) 48
Products under Development by Companies, H1 2013 (Contd..8) 49
Products under Development by Companies, H1 2013 (Contd..9) 50
Products under Development by Companies, H1 2013 (Contd..10) 51
Products under Development by Companies, H1 2013 (Contd..11) 52
Products under Development by Companies, H1 2013 (Contd..12) 53
Products under Development by Companies, H1 2013 (Contd..13) 54
Products under Development by Companies, H1 2013 (Contd..14) 55
Products under Development by Companies, H1 2013 (Contd..15) 56
Products under Development by Companies, H1 2013 (Contd..16) 57
Products under Development by Companies, H1 2013 (Contd..17) 58
Products under Development by Companies, H1 2013 (Contd..18) 59
Products under Development by Companies, H1 2013 (Contd..19) 60
Products under Development by Companies, H1 2013 (Contd..20) 61
Products under Investigation by Universities/Institutes, H1 2013 62
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 63
Alcon, Inc., H1 2013 64
Johnson and Johnson, H1 2013 65
Boehringer Ingelheim GmbH, H1 2013 66
F. Hoffmann-La Roche Ltd., H1 2013 67
Kyowa Hakko Kirin Co., Ltd., H1 2013 68
Amgen Inc., H1 2013 69
Antares Pharma, Inc., H1 2013 70
Sanofi-Aventis, H1 2013 71
Eli Lilly and Company, H1 2013 72
GlaxoSmithKline plc, H1 2013 73
Genentech, Inc., H1 2013 74
MedImmune LLC, H1 2013 75
Biotest AG, H1 2013 76
Merck and Co., Inc., H1 2013 77
Ablynx, H1 2013 78
AbGenomics International, Inc., H1 2013 79
Emergent BioSolutions Inc., H1 2013 80
Novo Nordisk A/S, H1 2013 81
BioLineRx, Ltd., H1 2013 82
MediGene AG, H1 2013 83
Nycomed International Management GmbH, H1 2013 84
TiGenix NV, H1 2013 85
Actelion Ltd, H1 2013 86
Astellas Pharma Inc., H1 2013 87
Biocon Limited, H1 2013 88
Eisai Co., Ltd., H1 2013 89
Elan Corporation, plc, H1 2013 90
Glenmark Pharmaceuticals Ltd., H1 2013 91
GTC Biotherapeutics, Inc., H1 2013 92
Japan Tobacco Inc., H1 2013 93
Kissei Pharmaceutical Co., Ltd., H1 2013 94
LEO Pharma A/S, H1 2013 95
Pfizer Inc., H1 2013 96
Rigel Pharmaceuticals, Inc., H1 2013 97
Santarus, Inc., H1 2013 98
Teva Pharmaceutical Industries Limited, H1 2013 99
UCB Group, H1 2013 100
Genmab A/S, H1 2013 101
Hadasit Medical Research Services and Development Ltd, H1 2013 102
Exelixis, Inc., H1 2013 103
Celgene Corporation, H1 2013 104
Onyx Pharmaceuticals, Inc., H1 2013 105
Incyte Corporation, H1 2013 106
Merck KGaA, H1 2013 107
4SC AG, H1 2013 108
Evotec Aktiengesellschaft, H1 2013 109
Genesis Research and Development Corporation Ltd., H1 2013 110
Hollis-Eden Pharmaceuticals, Inc., H1 2013 111
Celldex Therapeutics, Inc., H1 2013 112
Momenta Pharmaceuticals, Inc., H1 2013 113
Active Biotech AB, H1 2013 114
IMMUNOMEDICS, INC, H1 2013 115
Idera Pharmaceuticals, Inc., H1 2013 116
Karo Bio, H1 2013 117
Almirall, S.A., H1 2013 118
NexMed, Inc., H1 2013 119
Cleveland BioLabs, Inc., H1 2013 120
Compugen Ltd., H1 2013 121
Ore Pharmaceuticals Inc, H1 2013 122
Pharmos Corporation, H1 2013 123
Accentia Biopharmaceuticals, Inc., H1 2013 124
Arena Pharmaceuticals, Inc., H1 2013 125
Portola Pharmaceuticals, Inc., H1 2013 126
Chelsea Therapeutics, Inc., H1 2013 127
KOLON LIFE SCIENCE INC., H1 2013 128
NeoStem, Inc., H1 2013 129
Pharmacyclics, Inc., H1 2013 130
Protalix BioTherapeutics, Inc., H1 2013 131
Dynavax Technologies Corporation, H1 2013 132
Tolerx, Inc., H1 2013 133
ProMetic Life Sciences Inc., H1 2013 134
XOMA Ltd., H1 2013 135
Antisoma plc, H1 2013 136
Transgene SA, H1 2013 137
Hanall Pharmaceutical Co., Ltd., H1 2013 138
Panacea Biotec Limited, H1 2013 139
Catalyst Biosciences, Inc., H1 2013 140
Innate Pharma SA, H1 2013 141
DiaMedica Inc., H1 2013 142
Hansa Medical AB, H1 2013 143
R-Tech Ueno, Ltd., H1 2013 144
Cellerant Therapeutics, Inc., H1 2013 145
University of Erlangen-Nurnberg, H1 2013 146
Morphotek, Inc., H1 2013 147
Affitech A/S, H1 2013 148
Debiopharm Group, H1 2013 149
Advinus Therapeutics Pvt. Ltd., H1 2013 150
Axxam SpA, H1 2013 151
Alba Therapeutics Corporation, H1 2013 152
Ambit Biosciences Corporation, H1 2013 153
Viron Therapeutics, Inc., H1 2013 154
Deltanoid Pharmaceuticals Inc., H1 2013 155
Immupharma Plc, H1 2013 156
Palau Pharma S.A, H1 2013 157
Memgen, LLC., H1 2013 158
Molecular Partners AG, H1 2013 159
Pieris AG, H1 2013 160
Phenex Pharmaceuticals AG, H1 2013 161
conoGenetix biosciences GmbH, H1 2013 162
Hutchison MediPharma Limited, H1 2013 163
CREABILIS Therapeutics S.r.l., H1 2013 164
ERYtech Pharma, H1 2013 165
Affibody AB, H1 2013 166
Argos Therapeutics, Inc., H1 2013 167
Aegera Therapeutics Inc., H1 2013 168
Alligator Bioscience AB, H1 2013 169
Altor BioScience Corporation, H1 2013 170
Anacor Pharmaceuticals, Inc., H1 2013 171
AnaptysBio, Inc., H1 2013 172
Telormedix SA, H1 2013 173
Therapeutics Incorporated, H1 2013 174
Allozyne, Inc., H1 2013 175
ZaBeCor Pharmaceuticals, H1 2013 176
Chiome Bioscience, Inc., H1 2013 177
MacroGenics, Inc., H1 2013 178
Recoly N.V., H1 2013 179
Astion Pharma A/S, H1 2013 180
Five Prime Therapeutics, Inc., H1 2013 181
Vaccinex, Inc., H1 2013 182
Pantarhei Bioscience BV, H1 2013 183
Kineta, Inc., H1 2013 184
Deciphera Pharmaceuticals, LLC, H1 2013 185
MSM Protein Technologies, Inc., H1 2013 186
Reata Pharmaceuticals, Inc., H1 2013 187
Vascular Biogenics Ltd., H1 2013 188
Xention Limited, H1 2013 189
TcL Pharma SAS, H1 2013 190
Biotica Technology Ltd, H1 2013 191
VLST Corporation, Inc., H1 2013 192
Virobay Inc., H1 2013 193
NKT Therapeutics, Inc., H1 2013 194
Omeros Corporation, H1 2013 195
The Scripps Research Institute, H1 2013 196
Xencor, Inc., H1 2013 197
Cornerstone Therapeutics Inc., H1 2013 198
SBI Biotech Co., Ltd., H1 2013 199
iBio, Inc., H1 2013 200
ChemoCentryx, Inc., H1 2013 201
4-Antibody AG, H1 2013 202
CBio Limited, H1 2013 203
VentiRx Pharmaceuticals, Inc., H1 2013 204
Anthera Pharmaceuticals‚ Inc., H1 2013 205
Biokine Therapeutics Ltd., H1 2013 206
KYORIN Pharmaceutical Co., Ltd., H1 2013 207
Avesthagen Limited, H1 2013 208
Maruho Co.,Ltd., H1 2013 209
KAHR medical Ltd., H1 2013 210
SuppreMol GmbH, H1 2013 211
NasVax Ltd., H1 2013 212
Centocor Ortho Biotech, Inc., H1 2013 213
AIMM Therapeutics B.V., H1 2013 214
Zymeworks Inc., H1 2013 215
Anaphore, Inc., H1 2013 216
Dynamix Pharmaceuticals Ltd., H1 2013 217
Amplimmune, Inc., H1 2013 218
Lycera Corp., H1 2013 219
Perseid Therapeutics LLC, H1 2013 220
LFB Biotechnologies, S.A.S.U., H1 2013 221
Interprotein Corporation, H1 2013 222
CalciMedica, Inc., H1 2013 223
Zyngenia, Inc., H1 2013 224
MicroDose Therapeutx, Inc., H1 2013 225
Bio Sidus S.A., H1 2013 226
Gliknik, Inc., H1 2013 227
XBiotech USA, Inc., H1 2013 228
RaQualia Pharma Inc., H1 2013 229
Advancell, H1 2013 230
Assessment by Monotherapy Products, H1 2013 231
Assessment by Combination Products, H1 2013 232
Assessment by Stage and Route of Administration, H1 2013 235
Assessment by Stage and Molecule Type, H1 2013 238
Autoimmune Disorders Therapeutics - Drug Profile Updates 281
Autoimmune Disorders Therapeutics - Discontinued Products 313
Autoimmune Disorders Therapeutics - Discontinued Products (Contd..1) 314
Autoimmune Disorders Therapeutics - Dormant Products 315
Autoimmune Disorders Therapeutics - Dormant Products (Contd..1) 316
Autoimmune Disorders Therapeutics - Dormant Products (Contd..2) 317
Autoimmune Disorders Therapeutics - Dormant Products (Contd..3) 318
Autoimmune Disorders Therapeutics - Dormant Products (Contd..4) 319
Autoimmune Disorders Therapeutics - Dormant Products (Contd..5) 320
Autoimmune Disorders Therapeutics - Dormant Products (Contd..6) 321
Autoimmune Disorders Therapeutics - Dormant Products (Contd..7) 322
Autoimmune Disorders Therapeutics - Dormant Products (Contd..8) 323
Autoimmune Disorders Therapeutics - Dormant Products (Contd..9) 324
Autoimmune Disorders Therapeutics - Dormant Products (Contd..10) 325
Autoimmune Disorders Therapeutics - Dormant Products (Contd..11) 326



List of Figures

Number of Products under Development for Autoimmune Disorders, H1 2013 17
Products under Development for Autoimmune Disorders - Comparative Analysis, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Investigation by Universities/Institutes, H1 2013 34
Late Stage Products, H1 2013 37
Mid Clinical Stage Products, H1 2013 38
Early Clinical Stage Products, H1 2013 39
Discovery and Pre-Clinical Stage Products, H1 2013 40
Assessment by Monotherapy Products, H1 2013 231
Assessment by Combination Products, H1 2013 232
Assessment by Route of Administration, H1 2013 233
Assessment by Stage and Route of Administration, H1 2013 234
Assessment by Molecule Type, H1 2013 236
Assessment by Stage and Molecule Type, H1 2013 237

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Blood Disease Statistics

  • December 2016
    8 pages
  • Therapy  

    Blood Disease  

View report >

Cardiovascular Disease Statistics in the US

  • December 2016
    171 pages
  • Cardiovascular ...  

    Therapy  

  • United States  

View report >

Public Health Industry in the UK

  • December 2016
    156 pages
  • Public Health  

    Neurological Di...  

    Hospital  

  • United Kingdom  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.